Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Is Dan on March Break ?

<< Previous

Bullboard Posts

Next >>

Post by TechMooseon Mar 11, 2024 6:25pm

345 Views

Post# 35927393

Is Dan on March Break ?

The current lack of communication from Antibe management shows a complete disregard for shareholders. A formal statement issued about the Nuance arbitration ruling is not enough.

Let me give you some free advice Dan. Investor Relations 101 is all about clear communications. You don't have to tell us "everything" that's going on. But at least let us know the team is working on the situation. You know..."proof of life"

If your investor relations people are telling you to get a statement out, then listen to them. If they're not ....fire them.

Antibe is looking like a clown car right now.

<< Previous

Bullboard Posts

Next >>

How a junior advances one of the largest undeveloped diamond projects